Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Soft Tissue Sarcoma
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
Targeted Therapies in Oncology - 2017
2018
|
2017
|
2016
|
2015
|
2014
|
2013
|
2012
January 2017
February 2017
March 2017
April 2017
May 2017
June 2017
July 2017
August 2017
September 2017
October 2017
November 2017
December 2017
JTT Articles
The Role of JAK2 Inhibition in Polycythemia Vera
Current and Emerging Immunotherapy Strategies in Advanced Urothelial Cancers
Small Cell Transformation: An Increasingly Common Mechanism of Resistance in EGFR-Mutated Lung Cancer
>> View Peer-Reviewed Articles
Most Popular
A Look Back at FDA News from November 2018
MRD Could See More Use as Biomarker or Endpoint in the Future, FDA Says
Promise Is Seen in Newer EGFR TKIs to Overcome Resistance in NSCLC
Eng Provides Insight on Current Treatment Paradigm of GI Cancers
